Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy
Status:
Not yet recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
To establish efficacy and safety of HDM sublingual Immunotherapy (HDM-SLIT) by comparing
Odactra and placebo, when given sublingually for 3 years to high risk infants aged between 6
to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after
discontinuation of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Children's Hospital
Collaborators:
Children's Hospital Medical Center, Cincinnati Emory University George Washington University Imperial College London University of North Carolina, Chapel Hill University of Southampton